ProShare Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-11,563
| Closed | -$39K | – | 1790 |
|
|
2018
Q3 | $39K | Sell |
11,563
-887
| -7% | -$3.2K | ﹤0.01% | 1739 |
|
|
2018
Q2 | $47K | Buy |
12,450
+1,002
| +9% | +$4.88K | ﹤0.01% | 1755 |
|
|
2018
Q1 | $47K | Sell |
11,448
-1,848
| -14% | -$8.61K | ﹤0.01% | 1679 |
|
|
2017
Q4 | $62K | Buy |
+13,296
| New | +$73.3K | ﹤0.01% | 1755 |
|
|
2017
Q1 | – | Sell |
-12,682
| Closed | -$74K | – | 1706 |
|
|
2016
Q4 | $74K | Buy |
+12,682
| New | +$69.3K | ﹤0.01% | 1702 |
|
|
2016
Q2 | – | Sell |
-12,682
| Closed | -$59K | – | 1634 |
|
|
2016
Q1 | $59K | Sell |
12,682
-2,399
| -16% | -$9.57K | ﹤0.01% | 1549 |
|
|
2015
Q4 | $76K | Buy |
+15,081
| New | +$71.7K | ﹤0.01% | 1656 |
|
|
2015
Q3 | – | Sell |
-13,073
| Closed | -$130K | – | 1608 |
|
|
2015
Q2 | $130K | Sell |
13,073
-6,468
| -33% | -$69.4K | ﹤0.01% | 1566 |
|
|
2015
Q1 | $249K | Sell |
19,541
-99
| -0.5% | -$1.27K | ﹤0.01% | 1586 |
|
|
2014
Q4 | $278K | Sell |
19,640
-16,692
| -46% | -$259K | ﹤0.01% | 1566 |
|
|
2014
Q3 | $500K | Sell |
36,332
-8,235
| -18% | -$126K | 0.01% | 1412 |
|
|
2014
Q2 | $685K | Sell |
44,567
-45,763
| -51% | -$649K | 0.01% | 1379 |
|
|
2014
Q1 | $1.54M | Buy |
+90,330
| New | +$1.36M | 0.02% | 940 |
|
|
2013
Q4 | – | Sell |
-51,623
| Closed | -$521K | – | 2132 |
|
|
2013
Q3 | $521K | Sell |
51,623
-1,367
| -3% | -$12.2K | 0.01% | 1434 |
|
|
2013
Q2 | $396K | Buy |
+52,990
| New | +$414K | 0.01% | 1500 |
|
ProShare Advisors's KERX Position: Q4 2018 in Review
ProShare Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 11,563 shares — an estimated $39K sold.
ProShare Advisors first reported a position in KERX in Q2 2013 and held it in 15 quarters. The position peaked at $1.54M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- ProShare Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- ProShare Advisors sold 11,563 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $39K.
- ProShare Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- ProShare Advisors's Keryx Biopharmaceuticals Inc position peaked at $1.54M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.